Molecular Formula | C11H17ClO7P2 |
Molar Mass | 358.65 |
Solubility | DMSO: 5mg/mL |
Appearance | crystalline |
Color | white |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
In vitro study | Mifobate (100-400 μM; pretreated with 24 hours) significantly inhibits BRL 49653- and hormone-induced adipocyte differentiation of 3T3-L1 cells in a dose-dependent manner after 6 days. Mifobate is able to both interact specifically with PPARγ and inhibit its agonist-dependent interaction with the coactivator steroid receptor coactivator-1 (SRC-1). Mifobate (SR-202) inhibits TZD-stimulated recruitment of the coactivator steroid receptor coactivator-1. Mifobate blocks adipocyte differentiation induced either by thiazolidinediones or by the combination of dexamethasone, insulin, and 3-isobutyl-1-methylxanthine (IBMX). |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 2 |
RTECS | TB8817000 |
biological activity | Mifobate (SR-202) is a potent and specific antagonist of PPAR gamma, selective inhibition of thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μm). Mifobate does not affect basal or ligand-stimulated transcriptional activity of PPAR alpha, PPAR beta or FXR. Mifobate has anti-obesity and anti-diabetic effects. |
Animal Model: | Eight-week-old male ob/ob mice |
Dosage: | 400 mg/kg |
Administration: | Feed (food admixture maintained for 20 days) |
Result: | Prevented the time-dependent increase in glucose concentrations. |